Exelixis

Latest articles

7d
FOX Business
Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dipacquisitions for $2.35 billion. Tesla Inc., down $4.97 to $350.60 The electri
FOX Business / Posted 7 days ago
acquisitions for $2.35 billion. Tesla Inc., down $4.97 to $350.60 The electric car maker fired several hundred workers. Exelixis Inc., up $4.26 to $29.02 The company reported positive study results for its cancer drug Cabometyx. Ruby Tuesday... Read more
7d
FOX Business
Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dipacquisitions for $2.35 billion. Tesla Inc., down $4.97 to $350.60 The electri
FOX Business / Posted 7 days ago
acquisitions for $2.35 billion. Tesla Inc., down $4.97 to $350.60 The electric car maker fired several hundred workers. Exelixis Inc., up $4.26 to $29.02 Continue Reading Below The company reported positive study results for its cancer drug... Read more
7d
The Register Citizen
Financials, tech companies lead US stocks slightly higherwill buy Australian defense technology company Sigma Bravo. Shares in KBR added
The Register Citizen / Posted 7 days ago
will buy Australian defense technology company Sigma Bravo. Shares in KBR added 69 cents to $18.34. PROMISING TREATMENT: Exelixis vaulted 18.1 percent after the company reported positive study results for its cancer drug Cabometyx and said... Read more
379 related articles
7d
WFMZ Eastern Pennsylvania and Western New Jersey
Financials, tech companies lead US stocks slightly higherwill buy Australian defense technology company Sigma Bravo. Shares in KBR added
WFMZ Eastern Pennsylvania and Western New Jersey / Posted 7 days ago
will buy Australian defense technology company Sigma Bravo. Shares in KBR added 80 cents to $18.45. PROMISING TREATMENT: Exelixis vaulted 25.1 percent after the company reported positive study results for its cancer drug Cabometyx and said... Read more
379 related articles
7d
FOX Business
Exelixis liver cancer drug meets late-stage goal, shares jumpOct 16 (Reuters) - Exelixis Inc. (NASDAQ:EXEL) said on Monday its drug to treat
FOX Business / Posted 7 days ago
Oct 16 (Reuters) - Exelixis Inc. (NASDAQ:EXEL) said on Monday its drug to treat patients with a type of liver cancer met the main goal in a late stage study, sending its shares up 19 percent in premarket trading. The drug, cabozantinib, showed... Read more
7d
FOX Business
Exelixis liver cancer drug meets late-stage goal, shares jumpOct 16 (Reuters) - Exelixis Inc. (EXEL) said on Monday its drug to treat patien
FOX Business / Posted 7 days ago
Oct 16 (Reuters) - Exelixis Inc. (EXEL) said on Monday its drug to treat patients with a type of liver cancer met the main goal in a late stage study, sending its shares up 19 percent in premarket trading. Continue Reading Below The drug,... Read more
7d
Business Wire
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaIpsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today
Business Wire / Posted 7 days ago
Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and... Read more
4 related articles
7d
Business Wire
Ipsen annonce que l'étude de phase 3 CELESTIAL avec le cabozantinib atteint son critère d'évaluation principal de survie globale chez des patients atteints de carcinome hépatocellulaire avancéIpsen (EURONEXT : IPN ; ADR : IPSEY) et son partenaire Exelixis (NASDAQ : EXEL)
Business Wire / Posted 7 days ago
Ipsen (EURONEXT : IPN ; ADR : IPSEY) et son partenaire Exelixis (NASDAQ : EXEL) ont annoncé aujourd'hui que l’étude internationale de phase 3 CELESTIAL avait atteint son critère d'évaluation principal de survie globale, le cabozantinib ayant permis... Read more
78 related articles
7d
Business Wire
Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) toda
Business Wire / Posted 7 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and... Read more
4 related articles
18d
FOX Business
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in SeptemberShares of Exelixis(NASDAQ: EXEL), a biotech company focused on the development
FOX Business / Posted 18 days ago
Shares of Exelixis(NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global Market Intelligence. Two factors, including new clinical data... Read more
18d
FOX Business
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in SeptemberContinue Reading Below Shares of Exelixis(NASDAQ: EXEL), a biotech company foc
FOX Business / Posted 18 days ago
Continue Reading Below Shares of Exelixis(NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global Market Intelligence. Two factors,... Read more
23d
FOX Business
Exelixis, Inc. vs. Immunogen, Inc.It's been a really good year for Exelixis(NASDAQ: EXEL). The biotech's share pr
FOX Business / Posted 23 days ago
It's been a really good year for Exelixis(NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen(NASDAQ:... Read more
3 related articles
23d
FOX Business
Exelixis, Inc. vs. Immunogen, Inc.It's been a really good year for Exelixis(NASDAQ: EXEL). The biotech's share pr
FOX Business / Posted 23 days ago
It's been a really good year for Exelixis(NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen(NASDAQ:... Read more
3 related articles
28d
Business Wire
Exelixis Provides Update on Collaborator Daiichi Sankyo’s Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal StudySOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) tod
Business Wire / Posted 28 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive top-line results from a phase 3 pivotal trial of esaxerenone (INN;... Read more
1m
FOX Business
Why Exelixis, Inc. Slumped TodayWhat happened Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an a
FOX Business / Posted a month ago
What happened Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing to the downward direction of the share... Read more
1m
FOX Business
Why Exelixis, Inc. Slumped TodayWhat happened Continue Reading Below Exelixis(NASDAQ: EXEL) is down 12.3% at
FOX Business / Posted a month ago
What happened Continue Reading Below Exelixis(NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing to the downward... Read more
1m
FOX Business
These 3 Stocks Are Priced for Perfection. Can They Deliver?strong sales and earnings growth every quarter. Three healthcare stocks are es
FOX Business / Posted a month ago
strong sales and earnings growth every quarter. Three healthcare stocks are especially priced for perfection right now: Exelixis(NASDAQ: EXEL), Illumina(NASDAQ: ILMN), and Veeva Systems(NYSE: VEEV). What gives these stocks such premium... Read more
1m
FOX Business
These 3 Stocks Are Priced for Perfection. Can They Deliver?growth every quarter. Continue Reading Below Three healthcare stocks are espe
FOX Business / Posted a month ago
growth every quarter. Continue Reading Below Three healthcare stocks are especially priced for perfection right now: Exelixis(NASDAQ: EXEL), Illumina(NASDAQ: ILMN), and Veeva Systems(NYSE: VEEV). What gives these stocks such premium... Read more

In this news